Inc. BIO posted first-quarter 2019 adjusted earnings
per share (EPS) of $1.65, which beat the Zacks Consensus Estimate
by 47.3%. The bottom line also soared 41% from the prior-year
Reported EPS in the quarter was $28.74, compared
with $21.77 a year ago.
Revenues in Detail
Revenues in the quarter totaled $554 million,
beating the Zacks Consensus Estimate by 0.9%. Revenues rose 0.5%
from the year-ago quarter (up 4% at constant currency or cc).
Per management, solid demand across many of its
key product lines led to growth across most geographical
Bio-Rad Laboratories, Inc. Price,
Consensus and EPS Surprise
Bio-Rad Laboratories, Inc. Price, Consensus and
EPS Surprise | Bio-Rad Laboratories, Inc. Quote
Sales at the Life
Sciences segment in the first quarter totaled $215.7
million, up 9.1% year over year and 12% at cc. Per management, the
upside reflects higher sales in the cell biology, droplet Digital
PCR, food safety, and process media products. On a geographic
basis, sales were particularly strong in the Americas.
Net sales at Clinical
Diagnostics totaled $334.1 million, down 4.8% on a
year-over-year basis. However, sales were down less than 1% cc. The
upside in the currency neutral sales was driven by autoimmune and
blood typing products. Sales during the first quarter of 2019 rose
in the Americas, offset by weakness in Asia Pacific and parts of
Gross profit in the reported quarter totaled
$311.8 million, up 3.2% from the prior-year quarter. Gross margin
came in at 56.3%, showing expansion of 148 basis points (bps).
Operating margin came in at 10.2%, up 230 bps.
2019 Guidance Reaffirmed
For 2019, the company has reaffirmed its revenue
growth guidance at 4-4.5% (cc). The Zacks Consensus Estimate for
the same is pegged at $2.36 billion.
Bio-Rad exited the first quarter of 2019 on a
solid note. We are upbeat about the significant year-over-year rise
in earnings. The company also witnessed strong revenue growth at
the Life Sciences segment on strength in cell biology, droplet
Digital PCR and other product lines. Further, solid revenue growth
across several geographies, especially the Americas, buoys
optimism. The solid expansion of both margins is also
On the flip side, revenues at the Clinical
Diagnostics segment declined in the reported quarter.
Zacks Rank & Key Picks
Bio-Rad currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks with solid results this
earnings season are Stryker Corporation SYK, DENTSPLY SIRONA XRAY
and CONMED Corporation CNMD, each carrying a Zacks Rank #2 (Buy).
You can see the complete list of todayâs Zacks #1 Rank
(Strong Buy) stocks here.
Stryker delivered first-quarter 2019 adjusted EPS
of $1.88, beating the Zacks Consensus Estimate by 2.2%. Meanwhile,
revenues of $3.52 billion were in line with the consensus
DENTSPLY reported adjusted EPS of 49 cents in the
first quarter of 2019, beating the Zacks Consensus Estimate of 38
cents. Revenues came in at $946.2 million and surpassed the Zacks
Consensus Estimate of $917.1 million.
CONMED posted first-quarter 2019 adjusted EPS of
57 cents, which exceeded the Zacks Consensus Estimate of 54 cents.
Also, revenues of $218.4 million outshined the consensus mark of
This Could Be the Fastest Way to Grow
Wealth in 2019
Research indicates one sector is poised to
deliver a crop of the best-performing stocks you'll find anywhere
in the market. Breaking news in this space frequently creates quick
double- and triple-digit profit opportunities. These companies are
changing the world â and owning their stocks could transform your
portfolio in 2019 and beyond. Recent trades from this sector have
generated +98%, +119% and
+164% gains in as little as 1 month.
Click here to see these breakthrough
stocks now >>
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free
Stryker Corporation (SYK) :
Free Stock Analysis Report
Bio-Rad Laboratories, Inc.
(BIO) : Free Stock Analysis Report
CONMED Corporation (CNMD) :
Free Stock Analysis Report
DENTSPLY SIRONA Inc. (XRAY)
: Free Stock Analysis Report
To read this article on
Zacks.com click here.
Zacks Investment Research